Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

Janssen, a pharmaceutical company of Johnson & Johnson, established more than 99 sites across the globe to enroll the more than 716 patients needed for the study. Synexus, which is the largest multi-national company entirely focused on the recruitment and running of clinical trials at its own dedicated research centers, exceeded its recruitment target by more than 50% at its Watermeyer site in Pretoria.

Synexus country manager Dr. Sanet Aspinall commented, “We are often able to exceed our pharma and CRO client’s expectations as we have a very effective enrollment team to recruit patients from the large pool of people surrounding our research centers. This team has developed a sophisticated outreach program which works closely with GPs, primary care clinics and public hospitals in order to find the right patients quickly.”

Linda Roach, the GCO country manager of Janssen Pharmaceuticals in South Africa said, “Within our regulatory environment here in South Africa, we need to partner with sites that can enroll quickly with quality data and can support our efforts to achieve our recruitment targets. Synexus Watermeyer site in Pretoria is one such site."

"This is of particularly importance in South Africa as regulatory timelines can be slow leaving a shorter time frame in which to find these patients. Selection of the right site and infrastructure for this study has proven that, the country can not only deliver but exceed the target number of patients,” Roach continued.

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs